Visit the original URL
Frontier Bio announced on January 2 that at present, the company is actively accelerating the Phase II/III clinical trial of FB2001 for injection to treat hospitalized patients with new coronavirus infection and the Phase II clinical trial of FB2001 for aerosol inhalation to treat patients with mild and common coronavirus infection. / Phase III clinical trials. As of December 31, 2022, the international multi-center, randomized, double-blind, placebo-controlled phase II/III clinical trial of FB2001 for injection has been approved by China, Australia, the Philippines and other countries, and the subjects have entered the group and administered. With the recent increase in the number of people infected with the new coronavirus in various cities, the company will actively promote the progress of clinical trials and speed up the enrollment of subjects. FB2001 for injection is intended to treat hospitalized patients infected with the novel coronavirus.
media reports
Interface interface 36Kr
related events
- Frontier Bio: The phase II/III clinical trial of FB2001 for injection in patients with new coronavirus infection has been approved2023-01-02
- CanSino Biologics: Phase III clinical trial of recombinant new coronavirus vaccine has begun2020-09-02
- Microsoft builds a chatbot to help patients match suitable clinical trials 2019-03-02
This article is transferred from: https://readhub.cn/topic/8mfwaJvAHZ5
This site is only for collection, and the copyright belongs to the original author.